Athenex provides update from fda type a meeting regarding oral paclitaxel plus encequidar for the treatment of metastatic breast cancer

Buffalo, n.y., july 06, 2021 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the company held a type a meeting with the u.s. food and drug administration (fda) during the second quarter of 2021 to discuss the deficiencies raised in the complete response letter (crl) received in february.
ATNX Ratings Summary
ATNX Quant Ranking